FFCD - PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus durvalumab versus FOLFIRI plus durvalumab and tremelimumab in second-line setting of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma

PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus durvalumab versus FOLFIRI plus durvalumab and tremelimumab in second-line setting of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma

Auteurs

David Tougeron, Laetitia Dahan, Ludovic Evesque, Karine Le Malicot, Farid El Hajbi, Thomas Aparicio, Olivier Bouché, Nathalie Bonichon Lamichhane, Benoist Chibaudel, Antoine Angelergues, Anaïs Bodere, Jean-Marc Phelip, May Mabro, Laure Kaluzinski, Caroline Petorin, Gilles Breysacher, Yves Rinaldi, Aziz Zaanan, Denis Smith, Marie-Claude Gouttebel, Clément Perret, Nicolas Etchepare, Jean-François Emile, Ivan Sanfourche, Frédéric Di Fiore, Côme Lepage, Pascal Artru, Christophe Louvet

Journal / Conférence

JAMA Oncology

Type de publication

Article

Etude

PRODIGE 59 - DURIGAST

Localisation

Estomac